Takeaways: Gilead’s pCPA agreement advances LYVDELZI toward broader Canadian access, strengthening its position in the PBC treatment market. Public reimbursement could reduce affordability barri...
Browsing Tag: autoimmune liver disease
Takeaways: Gilead’s pCPA agreement advances LYVDELZI toward broader Canadian access, strengthening its position in the PBC treatment market. Public reimbursement could reduce affordability barri...